Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Rome Resources hails 'transformational' year as drilling continues

(Sharecast News) - Rome Resources has reported its annual results for a "transformational year" following the reverse takeover of Pathfinder Minerals, move to AIM and significant fundraising during 2024. The company, which is pre-revenue, finished the year with a cash balance of £4.3m, up from £1.4m at the end of 2024.

This a result of the £4m raised at admission to AIM in July and the £4.2m raised from a strategic investor in December, minus the cost of drilling operations during the second half of the year.

During the year, the miner re-activated drilling at the Bisie North Field Camp upon admission to AIM, while drilling at its Kalayi tin prospect and the Mont Agoma tin, copper, zinc and silver prospect continued. By the end of the period, 3,443m of core had been recovered in the drilling campaign.

Looking forward, Rome highlighted "highly encouraging results" from its drill campaign, which are feeding into its maiden resource estimate. This has been paused as the company awaits outstanding assay results from more recent drilling.

"Additional drill results, including tin intercepts outside the core area of Mont Agoma, will be included in the maiden resource estimate, expected to be completed in September 2025, which will inform the board as to the next steps on the journey to a valuable resource in a world class play," said chair Klaus Eckhof.

Shares were down 3.8% at 0.28p by 1219 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.